USP Kinase Inhibitors Afatinib 439081-18-2 Gilotrif for Lung Cancer Treatment

Product Description

USP Kinase Inhibitors Afatinib 439081-18-2 Gilotrif for Lung Cancer Treatment 

1. Quick Details:
 

2. What is Afatinib

Afatinib is pronounced aff-a-tin-ib. It has the brand name Giotrif (jee-oh-triff). It is a type of biological therapy called a tyrosine kinase inhibitor (TKI). It is a treatment for non small cell lung cancer that has spread outside the lung or to other parts of the body.

It has received regulatory approval for use as a treatment for non-small cell lung cancer,although there is emerging evidence to support its use in other cancers such as breast cancer.

3. How afatinib works:

This type of drug works by blocking particular proteins on cancer cells that encourage the cancer to grow. Afatinib blocks proteins called epidermal growth factor receptors (EGFR). Cancers that have these receptors are called EGFR positive.

Between 10 and 15 people out of every 100 with non small cell lung cancer (10 to 15%) have EGFR positive cancer. Doctors check your cancer cells to see if they have the receptors before you have this treatment.

Afatinib may shrink the cancer or stop it growing for a time

4. Uses and fuction:

Afatinib is used to treat a certain type of lung cancer (non-small cell lung cancer) that has spread to other parts of the body. It belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

5. Mechanism of action:

Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that also irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. Afatinib is not only active against EGFR mutations targeted by first generation tyrosine-kinase inhibitors (TKIs) likeerlotinib or gefitinib, but also against mutations such as T790M which are not sensitive to these standard therapies.Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers.

6. COA: